본문으로 건너뛰기
← 뒤로

Acute Myeloid Leukemia with an FMS-like Tyrosine Kinase 3-tyrosine Kinase Domain Mutation Developing Gilteritinib-induced Differentiation Syndrome.

1/5 보강
Internal medicine (Tokyo, Japan) 📖 저널 OA 72.5% 2024: 6/6 OA 2025: 37/56 OA 2026: 63/84 OA 2024~2026 2026 Vol.65(5) p. 703-707 OA
Retraction 확인
출처

Kubara C, Kuriyama T, Hirakawa S, Tochigi T, Hayashi M, Matsuo Y, Eto T, Taniguchi S

📝 환자 설명용 한 줄

FMS-like tyrosine kinase 3 (FLT3) mutations are observed in 30% of acute myeloid leukemia (AML) cases and indicate a poor prognosis.

이 논문을 인용하기

↓ .bib ↓ .ris
APA Kubara C, Kuriyama T, et al. (2026). Acute Myeloid Leukemia with an FMS-like Tyrosine Kinase 3-tyrosine Kinase Domain Mutation Developing Gilteritinib-induced Differentiation Syndrome.. Internal medicine (Tokyo, Japan), 65(5), 703-707. https://doi.org/10.2169/internalmedicine.5656-25
MLA Kubara C, et al.. "Acute Myeloid Leukemia with an FMS-like Tyrosine Kinase 3-tyrosine Kinase Domain Mutation Developing Gilteritinib-induced Differentiation Syndrome.." Internal medicine (Tokyo, Japan), vol. 65, no. 5, 2026, pp. 703-707.
PMID 40738675 ↗

Abstract

FMS-like tyrosine kinase 3 (FLT3) mutations are observed in 30% of acute myeloid leukemia (AML) cases and indicate a poor prognosis. FLT3 inhibitors, such as gilteritinib, improve outcomes but may cause differentiation syndrome (DS) in approximately 3% of patients. We herein report a case of FLT3-tyrosine kinase domain-mutated AML treated with idarubicin and cytarabine, followed by a single dose of gilteritinib. The patient developed DS that required intubation. Initial steroid therapy was ineffective; however, steroid pulse therapy and additional idarubicin resolved the DS. This case shows that gilteritinib-induced DS can occur early and severely and requires prompt and aggressive management.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반

🟢 PMC 전문 열기